PAVmed Inc. (PAVM) CFO Dennis M. Mcgrath Purchases 3,000 Shares of Stock
PAVmed Inc. (NASDAQ:PAVM) CFO Dennis M. Mcgrath purchased 3,000 shares of PAVmed stock in a transaction dated Thursday, August 24th. The shares were acquired at an average cost of $4.22 per share, for a total transaction of $12,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of PAVmed Inc. (NASDAQ PAVM) opened at 4.19 on Tuesday. The firm has a 50-day moving average of $3.74 and a 200 day moving average of $4.76. PAVmed Inc. has a 12-month low of $2.54 and a 12-month high of $14.49. The stock’s market capitalization is $55.86 million.
PAVmed (NASDAQ:PAVM) last issued its earnings results on Monday, August 14th. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01. Equities analysts forecast that PAVmed Inc. will post ($0.72) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “PAVmed Inc. (PAVM) CFO Dennis M. Mcgrath Purchases 3,000 Shares of Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/29/pavmed-inc-pavm-cfo-dennis-m-mcgrath-purchases-3000-shares-of-stock.html.
Separately, ValuEngine lowered shares of PAVmed from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th.
A hedge fund recently bought a new stake in PAVmed stock. Fusion Family Wealth LLC bought a new position in PAVmed Inc. (NASDAQ:PAVM) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 55,745 shares of the company’s stock, valued at approximately $251,000. Fusion Family Wealth LLC owned 0.42% of PAVmed at the end of the most recent reporting period. Institutional investors own 0.80% of the company’s stock.
PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.
Receive News & Stock Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related stocks with our FREE daily email newsletter.